TPS (Transcranial Pulse Stimulation)
Non-invasive neuromodulation using focused acoustic pulses aimed at deeper brain structures, guided by individualized, imaging-informed targeting.
What it is & how it works
Non-invasive neuromodulation using focused acoustic (shockwave-based) pulses aimed at deeper brain structures than magnetic or electrical methods can typically reach, guided by individualized, imaging-informed targeting.
How it's done
Typically administered as a structured initial course of multiple sessions over roughly two to five weeks (commonly around 6–10 sessions), delivering several thousand focused pulses per session to individually mapped target regions, followed by periodic monthly booster sessions; each session is brief (tens of minutes), outpatient, and does not require anaesthesia.
Conditions it treats
Why Brain Bridge
TPS is offered within Brain Bridge's individualized, evidence-bounded model — used where imaging-informed assessment supports it, and always communicated as emerging rather than curative, in keeping with the clinic's stated commitment to not overstate outcomes in neurodegenerative disease.
Evidence & safety
Evidence in neurodegenerative disease is still emerging, and use outside its approved indication is off-label. In autism, TPS is an off-label use with early, developing evidence; it is considered only alongside core developmental therapy and after discussion with the family.
Related questions
No. TPS uses focused acoustic (shockwave-type) pulses rather than the magnetic fields used in TMS or the electrical current used in tDCS, which allows it to target deeper brain structures than these other non-invasive methods typically reach.
Evidence is still emerging. Early studies, including small randomized and retrospective analyses, report good tolerability and some improvement in cognitive or mood measures over several months, but the overall evidence base remains limited, and TPS is not a cure for the underlying neurodegenerative disease.